Please ensure Javascript is enabled for purposes of website accessibility

1 Cheap Biotech Stock to Buy

By Prosper Junior Bakiny - Updated Mar 16, 2020 at 6:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market is in sell-off mode, but that doesn't mean you should stop buying stocks.

The stock market is currently in a state of turmoil. Due to fears surrounding the rapid spread of the novel coronavirus around the world -- which has now been declared a pandemic by the World Health Organization (WHO) -- the three major U.S. stock market indexes have plunged.

Furthermore, things could get worse before they get better, and no one knows how much longer the potentially deadly disease will keep spreading. Many investors are choosing to refrain from buying stocks at the moment, but others see the current environment as an excellent opportunity to find quality stocks at a bargain. If you are in the latter group, one cheap biotech stock you should add to your buy list is Jazz Pharmaceuticals (JAZZ -0.93%)

Xyrem doing most of the heavy lifting...for now

Jazz's crown jewel is a sleep disorder drug called Xyrem. This product has been racking up growing sales of late. During the third quarter, sales of Xyrem were $435.4 million, compared to $374.8 million in the year-ago period. For the full year, Xyrem recorded sales of $1.6 billion, up by 16.9% compared to the fiscal year 2018.

Drug pills forming a question mark

Image Source: Getty Images.

However, Jazz currently relies heavily on Xyrem. During its fiscal year 2019, sales of Xyrem accounted for about 76% of the company's total revenue. This is a significant problem because Xyrem will likely see some competition in the future. West-Ward Pharmaceuticals, a subsidiary of Hikma Pharmaceuticals (HKMP.F 2.30%), will start selling a generic version of Xyrem in 2023. This could significantly hinder Xyrem's growth -- unless Jazz can find ways to decrease its top-line exposure to its best-selling drug. Fortunately, the company is looking to do just that. 

Jazz's pipeline is promising

Jazz boasts several exciting products in its pipeline or that are currently being evaluated by health regulators.

First, the company submitted a New Drug Application (NDA) for JZP-258 to the U.S. Food and Drug Administration (FDA) in January. JZP-258 is a potential treatment for cataplexy and excessive daytime sleepiness (EDS) associated with narcolepsy. Narcolepsy, a chronic sleep disorder that affects about one in 2,000 people in the U.S., is severely under-diagnosed: Up to 50% of those with this condition have not been diagnosed. Furthermore, narcolepsy is associated with other conditions, such as hypertension and cardiovascular disease. For those reasons, Jazz has high hopes for JZP-258.

Second, Jazz submitted an NDA to the FDA for Lurbinectedin for the treatment of relapsed small-cell lung cancer (SCLC). Lurbinectedin was granted a priority review by the FDA, which means the review process will be shorter than usual. 

There are about 30,000 cases of SCLC in the U.S. per year. The company said: "There remains a critical unmet need for patients with relapsed SCLC, as the treatment landscape has not changed substantially in more than two decades since the last new chemical entity, topotecan, was approved."  Jazz is expecting an answer from the FDA in mid-August, and if approved, Lurbinectedin could help the company decrease its top-line exposure to Xyrem. 

Should you buy? 

Jazz is currently trading at just 11.37 times past earnings and 7.42 times future earnings. And given that the company will likely find more products to supplement its crown jewel Xyrem, it is worth considering purchasing shares of this biotech stock right now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Jazz Pharmaceuticals plc Stock Quote
Jazz Pharmaceuticals plc
$155.24 (-0.93%) $-1.45
Hikma Pharmaceuticals PLC Stock Quote
Hikma Pharmaceuticals PLC
$18.19 (2.30%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.